Who Owns Enovis Company?

Enovis Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Enovis Corporation?

Enovis Corporation, formerly part of Colfax Corporation, emerged as an independent entity in April 2022. This strategic spin-off allowed the company to focus exclusively on its medical technology portfolio.

Founded in 1995 by Steven and Mitchell Rales, the company, then known as Colfax, aimed to build a global enterprise through strategic acquisitions. Today, Enovis is a leader in orthopedic solutions.

Who holds the reins of Enovis Corporation?

The origins of Enovis Corporation are rooted in its predecessor, Colfax Corporation, established in 1995 by brothers Steven Rales and Mitchell Rales. These founders, having previously achieved success with Danaher Corporation, aimed to replicate their strategy of building a global entity through strategic acquisitions and operational enhancements.

Founding Vision

The Rales brothers envisioned building a global enterprise by acquiring and integrating businesses. Their strategy focused on enhancing operations through a robust operational model.

Early Growth Strategy

Growth was primarily driven by strategic acquisitions. This approach laid the foundation for the company's future evolution into a specialized medical technology firm.

First Major Acquisition

A significant early move was the acquisition of approximately 93% of IMO Industries, Inc. in August 1997. This demonstrated their commitment to expanding through strategic purchases.

Operational Framework

The implementation of the Colfax Business System (CBS) was central to their operational strategy. This system was designed to drive efficiency and continuous improvement across acquired entities.

Founder Equity Details

Specific details regarding the founders' initial equity splits or shareholding percentages at inception are not publicly disclosed. The focus was on the execution of their acquisition and operational strategy.

Early Investment Landscape

Information on early backers, angel investors, or specific initial capital sources beyond the founders' direct involvement is not readily available in public records.

While the precise initial ownership structure and early investor details are not publicly detailed, the Rales brothers' strategic approach to building the company through acquisitions and operational enhancements defined its foundational years. Their vision for growth, exemplified by the early acquisition of IMO Industries, Inc., set the stage for the company's subsequent transformation. Understanding this Growth Strategy of Enovis is key to grasping its ownership trajectory.

Founders and Early Ownership Overview

The Rales brothers, Steven and Mitchell, founded the company, then known as Colfax Corporation, in 1995. Their strategy involved leveraging acquisitions to build a global enterprise, focusing on operational improvements through the Colfax Business System.

• Founders: Steven Rales and Mitchell Rales
• Founding Year: 1995
• Predecessor Company: Colfax Corporation
• Key Strategy: Acquisition and operational enhancement
• First Major Acquisition: IMO Industries, Inc. (August 1997)

Enovis SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership structure of Enovis Corporation has evolved significantly, beginning with its predecessor, Colfax Corporation, which went public in May 2008. A major shift occurred in 2019 with the acquisition of DJO Global, establishing a strong presence in the medical device sector. The company rebranded as Enovis Corporation in April 2022 after spinning off its industrial business, becoming an independent, publicly traded entity focused on medical technologies.

As of August 2025, Enovis Corporation, a publicly traded company on the NYSE under the ticker ENOV, has a market capitalization of approximately $1.73 billion USD. The Enovis stock ownership is largely concentrated among institutional investors, who held 98.97% of outstanding shares as of Q1 2025. This diversified ownership includes significant stakes from major financial institutions such as BlackRock, Inc., which held 15.6% of shares, and The Vanguard Group, Inc., with 11.19%. Individual insiders also maintain substantial holdings, with Steven M. Rales owning 18.47% and Mitchell P. Rales holding 15.19%. Bdt Capital Partners LLC is noted as the largest individual shareholder. The company's strategic direction, particularly its focus on the orthopedic market, has been bolstered by these ownership dynamics and key acquisitions, such as LimaCorporate in January 2024. Understanding the Enovis company ownership breakdown is crucial for assessing its strategic direction and market position.

Key Enovis Shareholders

Enovis Corporation's ownership is predominantly held by institutional investors, reflecting broad market confidence. Key stakeholders include major asset managers and significant individual investors.

• Institutional investors collectively own 98.97% of Enovis stock as of Q1 2025.
• BlackRock, Inc. is a major institutional holder with 15.6% ownership.
• The Vanguard Group, Inc. holds 11.19% of the company's shares.
• Steven M. Rales and Mitchell P. Rales are significant individual shareholders.
• Bdt Capital Partners LLC is the largest individual Enovis shareholder.
• The company's Mission, Vision & Core Values of Enovis guide its strategic growth.

Enovis PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors at Enovis Corporation is instrumental in guiding the company's strategic path and governance. As of May 2025, Sharon Wienbar holds the position of Chair of the Board, a role she assumed in May 2025. Damien McDonald, the Chief Executive Officer since May 12, 2025, also serves as a director.

Enovis operates under a standard voting structure where common shares generally follow a one-share-one-vote principle. Public disclosures do not indicate the presence of dual-class shares or special voting rights. While Steven and Mitchell Rales are noted as significant individual shareholders, their direct control through specific voting mechanisms is not publicly detailed. The company's corporate governance framework is elaborated upon in its annual proxy statements, providing insight into Enovis company ownership breakdown and Enovis stock ownership details.

Understanding Enovis Ownership

The ownership structure of Enovis Corporation is primarily determined by its shareholders. Understanding who owns Enovis is key to grasping its corporate direction.

• Enovis is a publicly traded company, meaning its stock is available for purchase by the general public.
• The board composition reflects a mix of executive leadership and independent directors, some with ties to major investment firms.
• Shareholder influence is typically exercised through voting rights attached to common stock.
• Recent filings do not highlight any activist investor campaigns or significant governance disputes impacting Enovis company major stakeholders.
• For a deeper dive into the competitive environment, explore the Competitors Landscape of Enovis.

Enovis Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Enovis Corporation's ownership landscape has seen significant evolution over the past three to five years, marked by its transition to an independent entity and strategic acquisitions. These changes reflect a focused strategy on expanding its medical technology offerings, particularly within the orthopedics sector.

The ownership structure of Enovis Corporation is predominantly characterized by institutional investor influence. As of August 2025, institutional investors held a substantial 98.45% of the company's stock. Major entities like BlackRock, Inc. and The Vanguard Group, Inc. have demonstrated confidence by increasing their holdings in the first quarter of 2025. Insider holdings represent a smaller portion, accounting for approximately 1.93% as of April 2025. This indicates a strong reliance on external investment capital to fuel the company's growth and strategic initiatives.

Institutional Investor Dominance

Institutional investors are the primary stakeholders in Enovis. Their continued investment signals confidence in the company's strategic direction and future performance.

Strategic Shift to Integration Mode

Following a period of acquisition-driven growth, Enovis is now prioritizing debt reduction and free cash flow generation, shifting towards an integration-focused strategy.

Financial Performance and Outlook

For the full year 2024, Enovis reported net sales of $2.1 billion and adjusted EBITDA of $377 million. The company projects 2025 revenue between $2.19 billion and $2.22 billion, with adjusted EBITDA expected between $405 million and $415 million.

Key Growth Drivers

Industry trends such as the expansion of ambulatory surgical centers (ASCs) and the consistent growth in revision surgeries, estimated at 8-10% annually, are critical factors supporting Enovis's long-term strategy.

Enovis Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔